MSc BBA - Immutep Senior Strategy
| IMMP Stock | USD 2.03 0.06 3.05% |
Executive
MSc BBA is Senior Strategy of Immutep Ltd ADR
| Phone | 61 2 8315 7003 |
| Web | https://www.immutep.com |
Immutep Management Efficiency
The company has return on total asset (ROA) of (0.1667) % which means that it has lost $0.1667 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2621) %, meaning that it created substantial loss on money invested by shareholders. Immutep's management efficiency ratios could be used to measure how well Immutep manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Kevin CPA | Enveric Biosciences | 61 | |
| Esq CPA | Ocean Biomedical | 60 | |
| Robert Yang | Elevation Oncology | N/A | |
| Candice Masse | Elevation Oncology | N/A | |
| Biren Shah | Elevation Oncology | N/A | |
| MD MBA | Ocean Biomedical | 60 | |
| Melda Oconnell | ZyVersa Therapeutics | N/A | |
| Kimberly Davis | Zura Bio Limited | 57 | |
| Theresa Lowry | Zura Bio Limited | 51 | |
| MD FACC | ZyVersa Therapeutics | 75 | |
| Verender Badial | Zura Bio Limited | 53 | |
| Gary Whale | Zura Bio Limited | 50 | |
| Robert Sweeney | Ocean Biomedical | 60 | |
| Michael Howell | Zura Bio Limited | 47 | |
| Kiran MBBS | Zura Bio Limited | 52 | |
| David Brady | Zura Bio Limited | N/A | |
Management Performance
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.17 |
Immutep Ltd ADR Leadership Team
Elected by the shareholders, the Immutep's board of directors comprises two types of representatives: Immutep inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Immutep. The board's role is to monitor Immutep's management team and ensure that shareholders' interests are well served. Immutep's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Immutep's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Frederic MD, Chief Director | ||
| Deanne LLB, General COO | ||
| Indira Naidu, Joint Secretary | ||
| Christian Mueller, Director Affairs | ||
| Shengfei Fang, F Sec | ||
| MD MSc, Chief Officer | ||
| MSc BBA, Senior Strategy | ||
| Marc Voigt, CEO, Executive Director |
Immutep Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Immutep a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.17 | ||||
| Operating Margin | (13.53) % | ||||
| Current Valuation | 182.78 M | ||||
| Shares Outstanding | 145.46 M | ||||
| Shares Owned By Insiders | 0.01 % | ||||
| Shares Owned By Institutions | 6.30 % | ||||
| Number Of Shares Shorted | 5.06 M | ||||
| Price To Earning | (152.55) X | ||||
| Price To Book | 2.41 X |
Additional Tools for Immutep Stock Analysis
When running Immutep's price analysis, check to measure Immutep's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immutep is operating at the current time. Most of Immutep's value examination focuses on studying past and present price action to predict the probability of Immutep's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immutep's price. Additionally, you may evaluate how the addition of Immutep to your portfolios can decrease your overall portfolio volatility.